Sales fall but ZimVie boosts guidance
WESTMINSTER — ZimVie Inc. (Nasdaq: ZIMV), a medical technology company that manufactures devices for spinal surgery and oral reconstruction that was spun off last year from Zimmer Biomet Holdings Inc. (NYSE and SIX: ZBH), saw its year-over-year sales dip in the second quarter, but the firm is projecting full-year 2023 revenues will beat previous guidance.
The company posted net sales of $224.9 million in the second quarter of 2023, down 3.6% from the same period last year.
ZimVie’s net loss for the second quarter of 2023 was $23.4 million. That’s compared to a net loss of $8.7 million in the second quarter…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Columbine Health Systems will host Dementia Week, a series of free events devoted to educating…
-
Nextera Healthcare LLC and ImagineMD have combined to form a single direct-primary-care organization for employer…
-
LOVELAND — The Stinging Nettle has taken up residence in downtown, filling a hole recently…
-
OneOncology, a physician-led national platform for independent oncology practices, has acquired United Urology Group, a…
